1 / 29

Treatment of Chronic Hepatitis B in an HBeAg Positive Patient Geographical Area: America

History. 49-year-old man, bank employee, married, 2 kids.Consults a gastroenterologist for HBeAg CHB.Diagnosis had been established 3 years before, when donating blood (HBsAg positive). He had received 2-year therapy with lamivudine achieving HBV DNA negativization and ALT normalization within t

dericia
Download Presentation

Treatment of Chronic Hepatitis B in an HBeAg Positive Patient Geographical Area: America

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Treatment of Chronic Hepatitis B in an HBeAg Positive Patient Geographical Area: America

    11. Early viral suppression with Telbivudine leads to a reduced rate of resistance at 2 years in HBeAg-Pos patients References: CSR p367 Therapeutic Response=HBV DNA suppressed to = 5 log10, with ALT normalized OR HBeAg lossReferences: CSR p367 Therapeutic Response=HBV DNA suppressed to = 5 log10, with ALT normalized OR HBeAg loss

    15. Data from 5 studies High HBV DNA levels at 1 year are predictive of ADV resistance Two mutations detected: N236T A181V

    28. Early viral suppression with Telbivudine leads to a reduced rate of resistance at 2 years in HBeAg-Pos patients References: CSR p367 Therapeutic Response=HBV DNA suppressed to = 5 log10, with ALT normalized OR HBeAg lossReferences: CSR p367 Therapeutic Response=HBV DNA suppressed to = 5 log10, with ALT normalized OR HBeAg loss

More Related